Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults.

In a Phase 1 study, 15 healthy subjects were randomized to receive a 13-valent pneumococcal conjugate vaccine (PCV13) and 15 to receive a 23-valent pneumococcal polysaccharide vaccine (23vPS). Antibody responses were measured immediately before and approximately one month after vaccination. Serotype-specific antibodies were measured using an enzyme-linked immunosorbent assay (ELISA) for immunoglobulin G (IgG) and an opsonophagocytic assay (OPA) for functional antibodies. PCV13 was as immunogenic or more immunogenic than 23vPS and was well tolerated.

Full text links

Read article at publisher's site: https://doi.org/10.1016/j.vaccine.2007.06.004

References

Articles referenced by this article (13)

Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.
Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A; Active Bacterial Core Surveillance of the Emerging Infections Program Network
N Engl J Med, (18):1737-1746 2003
MED: 12724479
The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.
Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR
Clin Infect Dis, (1):122-140 2000
MED: 10619741
Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.
Hausdorff WP, Bryant J, Paradiso PR, Siber GR
Clin Infect Dis, (1):100-121 2000
MED: 10619740
Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States.
Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B; Active Bacterial Core Surveillance Team
J Infect Dis, (11):1988-1995 2005
MED: 16267772
Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.
Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, Benjamin W, Quataert SA, Hildreth S, Sikkema DJ, Kayhty H, Jonsdottir I, Nahm MH
Clin Diagn Lab Immunol, (4):514-519 2003
MED: 12853378
Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae.
Hu BT, Yu X, Jones TR, Kirch C, Harris S, Hildreth SW, Madore DV, Quataert SA
Clin Diagn Lab Immunol, (2):287-295 2005
MED: 15699424
Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial.
Ahmed F, Steinhoff MC, Rodriguez-Barradas MC, Hamilton RG, Musher DM, Nelson KE
J Infect Dis, (1):83-90 1996
MED: 8537687
Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults.
Shelly MA, Jacoby H, Riley GJ, Graves BT, Pichichero M, Treanor JJ
Infect Immun, (1):242-247 1997
MED: 8975918
Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults.
Wuorimaa T, Kayhty H, Leroy O, Eskola J
Vaccine, (15-16):1863-1869 2001
MED: 11228355
Significant variation in serotype-specific immunogenicity of the seven-valent Streptococcus pneumoniae capsular polysaccharide-CRM197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier protein.
Kamboj KK, Kirchner HL, Kimmel R, Greenspan NS, Schreiber JR
J Infect Dis, (10):1629-1638 2003
MED: 12721943

Show 3 more references (10 of 13)

Citations & impact

Impact metrics

Citations

Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/3672476

Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/3672476

Article citations

Optimization of the Process for Preparing Bivalent Polysaccharide Conjugates to Develop Multivalent Conjugate Vaccines against Streptococcus pneumoniae or Neisseria meningitidis and Comparison with the Corresponding Licensed Vaccines in Animal Models.
Huang F, Jing XB, Li YB, Wang Q, Liu SL, Yang ZR, Feng S
Curr Med Sci, 43(1):22-34, 21 Jan 2023
Cited by: 0 articles | PMID: 36680685 | PMCID: PMC9862236
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Missed vaccinations and critical care admission: all you may wish to know or rediscover-a narrative review.
Pittet LF, Abbas M, Siegrist CA, Pittet D
Intensive Care Med, 46(2):202-214, 26 Nov 2019
Cited by: 3 articles | PMID: 31773179 | PMCID: PMC7223872
Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Pneumococcal pep27 mutant immunization stimulates cytokine secretion and confers long-term immunity with a wide range of protection, including against non-typeable strains.
Kim GL, Choi SY, Seon SH, Lee S, Park SS, Song JY, Briles DE, Rhee DK
Vaccine, 34(51):6481-6492, 16 Nov 2016
Cited by: 8 articles | PMID: 27865564
Decreased Carriage and Genetic Shifts in the Streptococcus pneumoniae Population After Changing the Seven-valent to the Thirteen-valent Pneumococcal Vaccine in Norway.
Steens A, Caugant DA, Aaberge IS, Vestrheim DF
Pediatr Infect Dis J, 34(8):875-883, 01 Aug 2015
Cited by: 23 articles | PMID: 26020410
Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study.
Leventer-Roberts M, Feldman BS, Brufman I, Cohen-Stavi CJ, Hoshen M, Balicer RD
Clin Infect Dis, 60(10):1472-1480, 10 Feb 2015
Cited by: 32 articles | PMID: 25669354

Go to all (61) article citations

Search life-sciences literature (45,103,589 articles, preprints and more)

Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults.

Affiliations

Authors

ORCIDs linked to this article

Abstract

Full text links

References

Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States.

Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides.

Approach to validating an opsonophagocytic assay for Streptococcus pneumoniae.

Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial.

Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults.

Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults.

Significant variation in serotype-specific immunogenicity of the seven-valent Streptococcus pneumoniae capsular polysaccharide-CRM197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier protein.

Citations & impact

Impact metrics

Citations of article over time

Alternative metrics

Article citations

Optimization of the Process for Preparing Bivalent Polysaccharide Conjugates to Develop Multivalent Conjugate Vaccines against Streptococcus pneumoniae or Neisseria meningitidis and Comparison with the Corresponding Licensed Vaccines in Animal Models.

Missed vaccinations and critical care admission: all you may wish to know or rediscover-a narrative review.

Pneumococcal pep27 mutant immunization stimulates cytokine secretion and confers long-term immunity with a wide range of protection, including against non-typeable strains.

Decreased Carriage and Genetic Shifts in the Streptococcus pneumoniae Population After Changing the Seven-valent to the Thirteen-valent Pneumococcal Vaccine in Norway.

Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study.

Similar Articles

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.

Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease.

Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults.

Partnerships & funding

Similar Articles

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
Pediatrics, 125(5):866-875, 01 May 2010

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Pediatr Infect Dis J, 28(4 suppl):S77-88, 01 Apr 2009

Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease.
J Infect Dis, 181(3):1162-1166, 01 Mar 2000

Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults.
Vaccine, 30(30):4435-4444, 26 Apr 2012

Search life-sciences literature (45,103,589 articles, preprints and more)

Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults.

Author information

Affiliations

Authors

ORCIDs linked to this article

Abstract

Full text links

References

Citations & impact

Impact metrics

Citations of article over time

Alternative metrics

Article citations

Similar Articles

Partnerships & funding